Freeline Therapeutics Holdings plc
NASDAQ: FRLN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael J. Parini
- Employees
- 152
- Headquarters
- Stevenage, United Kingdom
- IPO year
- 2020
- Market cap
- $28.3M
- Website
- https://www.freeline.life
Loading FRLN…
Loading profile data…Frequently asked questions about FRLN
What does Freeline Therapeutics Holdings plc (FRLN) do?
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading t...
Where does FRLN trade?
Freeline Therapeutics Holdings plc (FRLN) trades on the NASDAQ Global Select.
What sector is FRLN in?
Freeline Therapeutics Holdings plc (FRLN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Freeline Therapeutics Holdings plc?
Michael J. Parini is the chief executive officer of Freeline Therapeutics Holdings plc (FRLN).
Where is Freeline Therapeutics Holdings plc headquartered?
Freeline Therapeutics Holdings plc is headquartered in United Kingdom.
Does FRLN pay a dividend?
Freeline Therapeutics Holdings plc (FRLN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FRLN go public?
Freeline Therapeutics Holdings plc (FRLN) completed its initial public offering in 2020.